Suppr超能文献

计算洞察 μ 阿片受体 G 蛋白偏向激活和失活机制。

Computational insights into the G-protein-biased activation and inactivation mechanisms of the μ opioid receptor.

机构信息

Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, Shanghai 200237, China.

Drug Discovery and Design Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.

出版信息

Acta Pharmacol Sin. 2018 Jan;39(1):154-164. doi: 10.1038/aps.2017.158. Epub 2017 Nov 30.

Abstract

The μ opioid receptor (OR), a member of the class A subfamily of G-protein coupled receptors (GPCRs), is a major target for the treatment of pain. G-protein biased μ-OR agonists promise to be developed as analgesics. Thus, TRV130, the first representative μ-OR ligand with G-protein bias, has entered into phase III clinical trials. To identify the detailed G-protein-biased activation and inactivation mechanisms of the μ-OR, we constructed five μ-OR systems that were in complexes with the G-protein-biased agonists TRV130 and BU72, the antagonists β-FNA and naltrexone, as well as the free receptor. We performed a series of conventional molecular dynamics simulations and analyses of G-protein-biased activation and inactivation mechanisms of μ-OR. Our results, together with previously reported mutation results, revealed the operating mode of the activation switch composed of residues W and Y (Ballesteros/Weinstein numbering), the activity of which was responsible for down- and up-regulation, respectively, of the β-arrestin signaling, which in turn affected G-protein-biased activation of μ-OR. TRV130 was found to stabilize W by interacting with Y. In addition, we obtained useful information regarding μ-OR-biased activation, such as strong stabilization of W through a hydrophobic ring interaction in the TRV130 system. These findings may facilitate understanding of μ-OR biased activation and the design of new biased ligands for GPCRs.

摘要

μ 阿片受体(μOR)是 G 蛋白偶联受体(GPCR)A 亚家族的成员,是治疗疼痛的主要靶点。G 蛋白偏向性 μOR 激动剂有望被开发为镇痛药。因此,TRV130,即第一个具有 G 蛋白偏向性的 μOR 配体,已进入 III 期临床试验。为了确定 μOR 的详细 G 蛋白偏向性激活和失活机制,我们构建了五个与 G 蛋白偏向性激动剂 TRV130 和 BU72、拮抗剂 β-FNA 和纳曲酮以及游离受体结合的 μOR 系统。我们进行了一系列常规分子动力学模拟和 μOR 的 G 蛋白偏向性激活和失活机制分析。我们的结果与先前报道的突变结果一起,揭示了由残基 W 和 Y 组成的激活开关的工作模式(Ballesteros/Weinstein 编号),其活性分别负责下调和上调β-抑制素信号,从而影响 μOR 的 G 蛋白偏向性激活。TRV130 被发现通过与 Y 相互作用稳定 W。此外,我们获得了有关 μOR 偏向性激活的有用信息,例如在 TRV130 系统中通过疏水性环相互作用对 W 进行强稳定。这些发现可能有助于理解 μOR 的偏向性激活和 GPCR 新的偏向性配体的设计。

相似文献

3
Mechanism of β-arrestin recruitment by the μ-opioid G protein-coupled receptor.μ 阿片型 G 蛋白偶联受体募集β-arrestin 的机制。
Proc Natl Acad Sci U S A. 2020 Jul 14;117(28):16346-16355. doi: 10.1073/pnas.1918264117. Epub 2020 Jun 29.

引用本文的文献

7
Encoding mu-opioid receptor biased agonism with interaction fingerprints.利用相互作用指纹编码 μ 阿片受体偏向激动作用。
J Comput Aided Mol Des. 2021 Nov;35(11):1081-1093. doi: 10.1007/s10822-021-00422-5. Epub 2021 Oct 29.

本文引用的文献

6
New Technologies for Elucidating Opioid Receptor Function.用于阐明阿片受体功能的新技术。
Trends Pharmacol Sci. 2016 Apr;37(4):279-289. doi: 10.1016/j.tips.2016.01.001. Epub 2016 Jan 29.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验